Clinical Application of Real-World Evidence for Stroke Prevention in Atrial Fibrillation and the Treatment of Venous Thromboembolism (CARE-AF/VTE Program)

Venous Thromboembolism Course Information

Description

Available evidence demonstrates that clinical practice in Europe and globally varies significantly from the recommendations of evidence-based guidelines for the treatment of venous thromboembolism (VTE). Gaps in clinician knowledge and the lack of established anticoagulation stewardship programs result in suboptimal patient outcomes due to under-use of anticoagulant therapy, inappropriate dosing, and poor clinical decision-making among patients in high-risk populations. The consideration of real-world evidence in clinical practice is extremely important, as not all populations receiving oral anticoagulation for the treatment of VTE have clear evidence on the best approach for management. Complex and high-risk patients have not been well-represented in major randomized controlled trials and published guidelines may not provide sufficient insights into the management of underrepresented patient groups or less common clinical scenarios.

Participants will explore clinical decision-making strategies and practical applications of real-world data to align treatment with current guidelines.

Lessons will be released weekly and then permanently available to registered attendees.

Faculty: Walter Ageno, MD

Session 1: Direct Oral Anticoagulant Use in Venous Thromboembolism
February 10, 2025

Learning Objectives:
After reviewing this educational module, participants will be better able to:

Evaluate the key findings from controlled trials supporting the efficacy and safety of Direct Oral Anticoagulants (DOACs) compared to Vitamin K Antagonists (VKAs) for treatment of venous thromboembolism (VTE)
Analyze how the efficacy and safety of DOACs in real-world settings compares to their performance in randomized controlled trials
Identify differences between individual DOACs in real-world practice and their clinical application in practice

Session 2: Direct Oral Anticoagulant Use in Special Populations with Venous Thromboembolism
February 17, 2025

Learning Objectives:
After reviewing this educational module, participants will be better able to:

Describe the adjustments needed for direct oral anticoagulant (DOAC) dosing in patients with renal or liver disease and in those at extremes of body weight (high or low)
Apply current evidence to determine how DOACs can be used in patients with cancer-associated venous thromboembolism (VTE)
Analyze the risks and benefits of using DOACs in patients with various congenital or acquired prothrombotic conditions

Session 3: Anticoagulation Stewardship of Direct Oral Anticoagulant Therapy in Venous Thromboembolism
February 24, 2025

Learning Objectives:
After reviewing this educational module, participants will be better able to:

Assess the factors that determine the appropriate duration of treatment for venous thromboembolism (VTE) with a direct oral anticoagulant (DOAC)
Evaluate the impact of patient adherence on the efficacy and safety of DOAC therapy using real-world data across the world
Define the role of anticoagulation stewardship in overcoming challenges and ensuring best practice in anticoagulant therapy

Session 4: Venous Thromboembolism – Q&A with Experts
March 3, 2025 | 4:00pm – 5:00pm CEST

Faculty: Walter Ageno, MD; Edelgard Lindhoff-Last, MD; Karina Meijer, MD, PhD; Antoni Martínez-Rubio, MD; and Scott Kaatz, DO, MSc (moderator)

Still have questions on the treatment of venous thromboembolism? Join our panel of international experts LIVE on Monday, March 3, 2025 from 4:00pm – 5:00pm CEST (Central European Standard Time). Submit your questions ahead of time through the learning module website.

Venous Thromboembolism Free Registration

Please log into your account to register for this course.

Accreditation CE Hours

This 4-week program is accredited for up to 2.5 hours of continuing education credits for physicians, nurses, and pharmacists.

Atrial Fibrillation Course Remember to register for the Atrial Fibrillation part of the course!

This program will focus on enhancing clinicians' understanding of the latest evidence-based practices for anticoagulation therapy in AF, addressing the underuse of DOACs and common dosing errors to improve patient care and outcomes. Participants will explore clinical decision-making strategies and practical applications of real-world data to align treatment with current guidelines.